Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.04), Zacks reports. The firm had revenue of $1.76 million for the quarter, compared to the consensus estimate of $2.54 million. Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%.
Arbutus Biopharma Stock Down 1.3%
Shares of NASDAQ:ABUS opened at $3.12 on Friday. Arbutus Biopharma has a 12 month low of $2.71 and a 12 month high of $4.73. The company’s fifty day simple moving average is $3.28 and its 200 day simple moving average is $3.38. The firm has a market cap of $597.42 million, a price-to-earnings ratio of -7.26 and a beta of 1.50.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on ABUS. StockNews.com raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, March 29th. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Arbutus Biopharma in a research report on Tuesday, January 21st. Finally, Chardan Capital reissued a “buy” rating and set a $5.00 price target on shares of Arbutus Biopharma in a research report on Friday, March 28th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Arbutus Biopharma presently has a consensus rating of “Moderate Buy” and an average price target of $5.50.
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
Featured Articles
- Five stocks we like better than Arbutus Biopharma
- Best Energy Stocks – Energy Stocks to Buy Now
- 3 Mid-Cap Stocks Turning Heads in AI, Automation, & Cybersecurity
- Insider Buying Explained: What Investors Need to Know
- Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades
- Health Care Stocks Explained: Why You Might Want to Invest
- Symbotic Gets Big Earnings Lift: Is the Stock Investable Again?
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
